C3 and cancer: With the burgeoning interest to increase the efficacy of prevailing chemotherapeutics through addressing intracellular molecular targets to sensitize cancer cells in multimodal treatments, our findings hold tremendous potential to harness therapeutically attractive protein enzymes such as the C3 enzyme for tumor growth inhibition and minimum drug dosage applied in combination with marketed chemotherapeutics.